Proactive Investors - Run By Investors For Investors

FSD Pharma bolsters its board of directors with a pair of fresh faces

BioAgilytix CEO James Datin and Broad Street Angels Vice Chairman Robert Ciaruffoli are joining the board
Boardroom
Jim Datin (pictured) has led BioAgilytix was to a spot on the Inc. 5000 list of Fastest Growing Private Companies in America six times

FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) is beefing up its board of directors, the company announced Wednesday.

James Datin, CEO of the bioanalytics lab BioAgilytix, and Robert Ciaruffoli, the co-founder and vice chairman of the 100-member angel investor network Broad Street Angels, are joining the board.

The company's stock was flat at C$0.20 in Toronto and climbed 0.8% to US$0.15 on OTC Markets.

Under Datin’s leadership, BioAgilytix was named to the Inc. 5000 list of Fastest Growing Private Companies in America six times and selected as the Contract Research Organization of the year in North Carolina. He oversaw the company’s expansion into Europe with the acquisition of Hamburg-based lab IPM Biotech.

READ: FSD Pharma adds two leading cannabis researchers to Scientific Advisory Board

Ciaruffoli, a CPA, helps lead the largest angel investor network in the Philadelphia region. Prior to that, he served as CEO and Chairman of the accounting firm Parente Beard/Baker Tilly. He transformed the firm from a Philadelphia company to a regional one. He oversaw the merger between the Parente Beard and Baker Tilly Virchow Krause firms, which created the 12th largest such firm in the US.

"It is an honor to welcome Jim Datin and Bob Ciaruffoli to the FSD Pharma Board of Directors," CEO and Co-Chairman Raza Bokhari said. "The experience and expertise they both bring as C-level entrepreneurial executives, leaders and board members of impressive organizations will add tremendous value to FSD. Both gentlemen have been instrumental in achieving outstanding growth for their respective companies, in raising capital to fuel growth opportunities and in driving sustainable shareholder value."

FSD Pharma is a producer of pharmaceutical grade cannabis with facilities in Toronto and Ontario. It operates a research and development platform focused on cannabinoid-based treatments for central nervous system disorders such as fibromyalgia and Irritable Bowel Syndrome.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full HUGE profile View Profile

FSD Pharma Timeline

Related Articles

cannabis facility
January 23 2019
The company is breaking into the large and lucrative market in the golden state
medicinal cannabis concept
January 30 2019
Zelda has released its December quarterly report confirming multiple trials are on track.
RYAH vaporizer and cartridges
May 16 2019
RYAH is the first cannabis vaporizer that lets users precisely regulate dose and temperature

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use